To the full analysis
Xvivo Perfusion stock: growth
XVIVO.STXvivo Perfusion reported $81.44M in revenue for fiscal 2025, down 1.2% on the prior year, up 35.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
36.1%
per year from 2012 to 2025, per share 31.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 35.2% | 21.0% | 36.1% |
| Revenue per share | 31.3% | 16.5% | 31.2% |
| Earnings | no data | 17.2% | no data |
| Earnings per share | no data | 12.8% | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $1.48M | −$77.11K | −$129.45K |
| 2013 | $6.91M | $807.59K | $87.64K |
| 2014 | $8.49M | $374.81K | −$1.88M |
| 2015 | $12.06M | $514.49K | −$464.36K |
| 2016 | $13.86M | $150.51K | −$798.36K |
| 2017 | $14.87M | $627.7K | −$1.28M |
| 2018 | $18.84M | $1.27M | −$3.12M |
| 2019 | $22.14M | $495.24K | −$5.43M |
| 2020 | $18.03M | −$4.39M | −$7.72M |
| 2021 | $25.91M | $817.41K | −$10.64M |
| 2022 | $41.64M | $1.85M | −$10.34M |
| 2023 | $59.92M | $9.21M | −$9.79M |
| 2024 | $82.46M | $17.26M | −$8.21M |
| 2025 | $81.44M | $2.52M | −$15.23M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 11 Nov 2026, previously Weak
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.